Autor segons l'article: Utrillo L, Vidal F, Puig T, Domingo P
Departament: Medicina i Cirurgia
Autor/s de la URV: Vidal Marsal, Francisco
Paraules clau: Virologically suppressed adults Toxicity Tenofovir disoproxil fumarate Switching Safety Reverse-transcriptase inhibitor Randomized comparative trial Pi Open-label Once-daily dolutegravir Nrti Nnrti Insti Infected patients Hiv-1-infected patients Combination antiretroviral therapy Boosted protease inhibitor Bone-mineral density switching safety pi nrti nnrti insti combination antiretroviral therapy
Resum: Introduction: There are multiple reasons to switch from a virologically successful antiretroviral regimen. Some of them are related to toxicity. Lately, combination antiretroviral treatment (cART) switches have often been related to drug-drug interactions which may also eventually entail safety issues as well. Areas covered: The purpose of this review is to analyze causes of switching between virologically successful cART regimes related to safety issues. The most relevant papers were selected and summarized. Expert opinion: Switching cART has been a popular strategy to address safety issues throughout the antiretroviral era. The myriad of switching studies have paralleled the study and release into clinical practice of new antiretroviral drugs with different and often improved safety profiles. Most of them have been successful in improving antiretroviral toxicity while keeping HIV replication under control. However, it should be taken into account that, whenever a new drug is given, there is a possibility of new drug-related toxicity. Notwithstanding that, an increase in cART switching is foreseen, given the fact that we have a wide antiretroviral drug armamentarium and that people living with HIV are ageing and thus more prone to developing age-related co-morbidities whose therapies may entail new interactions and eventually new toxicities.
Grup de recerca: Grup de Recerca Biomèdica HJ23
Àrees temàtiques: Saúde coletiva Pharmacology (medical) Pharmacology & pharmacy Medicine (miscellaneous) Medicina iii Medicina ii Medicina i Ciências biológicas i
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
Adreça de correu electrònic de l'autor: francesc.vidal@urv.cat
Identificador de l'autor: 0000-0002-6692-6186
Data d'alta del registre: 2024-09-07
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Enllaç font original: https://www.tandfonline.com/doi/full/10.1080/14740338.2016.1206076
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Expert Opinion On Drug Safety. 15 (10): 1349-1360
Referència de l'ítem segons les normes APA: Utrillo L, Vidal F, Puig T, Domingo P (2016). Switching antiretroviral regimes for the treatment of HIV: safety implications. Expert Opinion On Drug Safety, 15(10), 1349-1360. DOI: 10.1080/14740338.2016.1206076
DOI de l'article: 10.1080/14740338.2016.1206076
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2016
Tipus de publicació: Journal Publications